NCT07230470 Comparative Study of LoKomat® Exoskeleton VS C-Mill® Treadmill for Gait Recovery in Rehabilitation.
| NCT ID | NCT07230470 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidad Pontificia de Salamanca |
| Condition | Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-12-09 |
| Primary Completion | 2026-02-25 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-12-09 with a primary completion date of 2026-02-25.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The use of robotic technology for the treatment of gait in neurological pathologies has provided different results in scientific evidence. In patients with some types of acquired brain damage, such as stroke, the use of Lokomat® therapy can bring improvements in aspects such as gait speed and balance, among other parameters and report greater functional recovery in subacute patients with greater deterioration. Similarly, the use of another technological element such as the C-Mill® reports improvements in various aspects of ambulation and balance in gait treatments for stroke patients. Likewise, the impact on the person's recovery is not only beneficial for gait rehabilitation, but also improves the perception of well-being, which can be positive in the process of readaptation to daily life. The effect of both treatments for gait rehabilitation in adults with stroke and their impact on quality of life in the neurorehabilitation clinic will be studied. adults with stroke and their impact on quality of life at the Lescer neurorehabilitation clinic Lescer, Madrid (Spain). Participants will be assessed at baseline, 4 weeks, 8 weeks and 12 weeks.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of stroke (haemorrhagic and/or ischaemic) by a specialist physician. . * Subjects who are cognitively capable and who sign the informed consent form. Exclusion Criteria: * Severe cognitive impairment (Mini-Mental State Examination \< 24.), or impairment that prevents correct understanding of the correct understanding of the messages and explanatory orders of the treatment and its conditions. * Diagnosis of concomitant neurological diseases and craniocerebral trauma. cranioencephalic trauma. * Other diseases that interfere with the gait process (e.g. disabling arthritis or arthrosis, other neurological diseases, other neurological diseases). disabling arthritis or osteoarthritis, other concomitant neurological diseases, etc.). \- Contraindications of the robotic tools themselves.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07230470 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07230470 currently recruiting?
Yes, NCT07230470 is actively recruiting participants. Contact the research team at jvelazquezsa@upsa.es for enrollment information.
Where is the NCT07230470 trial being conducted?
This trial is being conducted at Salamanca, Spain.
Who is sponsoring the NCT07230470 clinical trial?
NCT07230470 is sponsored by Universidad Pontificia de Salamanca. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.